KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Preferred Shares (2016 - 2018)

Teva Pharmaceutical Industries' Preferred Shares history spans 4 years, with the latest figure at $3.8 billion for Q3 2018.

  • For the quarter ending Q3 2018, Preferred Shares changed N/A year-over-year to $3.8 billion, compared with a TTM value of $3.8 billion through Sep 2018, changed N/A, and an annual FY2017 reading of $3.6 billion, changed 0.3% over the prior year.
  • Preferred Shares for Q3 2018 was $3.8 billion at Teva Pharmaceutical Industries, up from $3.8 billion in the prior quarter.
  • The five-year high for Preferred Shares was $3.8 billion in Q3 2018, with the low at $3.3 billion in Q4 2015.
  • Average Preferred Shares over 4 years is $3.6 billion, with a median of $3.7 billion recorded in 2017.
  • Year-over-year, Preferred Shares grew 10.0% in 2016 and then rose 0.3% in 2017.
  • Tracing TEVA's Preferred Shares over 4 years: stood at $3.3 billion in 2015, then increased by 10.0% to $3.6 billion in 2016, then grew by 0.3% to $3.6 billion in 2017, then grew by 5.34% to $3.8 billion in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Preferred Shares are $3.8 billion (Q3 2018), $3.8 billion (Q2 2018), and $3.7 billion (Q1 2018).